2 Biotechs Get $1.9 Billion Vaccine Order

The U.S. government is pulling out the stops. Today the Department of Health & Human Services agreed to buy millions of new Covid-19 vaccines. The initial order includes 100… Read more

The Oxford Vaccine Results

Three new and promising Covid-19 vaccines are emerging. Oxford University is producing a vaccine in partnership with AstraZeneca (NYSE: AZN). The drug is already in Phase III vaccine trials… Read more

75,600 New Covid Cases in 24 Hours

Covid cases are spreading like a California wildfire. 75,600 new Covid cases were reported across the U.S. on Thursday. And that number shattered the previous coronavirus record of 68,241… Read more

Cambridge Biotech Plans 1 Billion Vaccines

Good news on the vaccine front! Biotechnology company Moderna (NASDAQ: MRNA) has been working on a vaccine to prevent coronavirus infections. Yesterday, the results of an early Phase 1… Read more

The Tiny Biotech With a Covid-19 Vaccine

Stocks are surging today. One Massachusetts biotech firm named Moderna (NASDAQ: MRNA) is creating a Covid-19 vaccine. And early results for the Moderna vaccine are very, very promising. Moderna… Read more

America’s New Covid Hotspot (not NYC)

63,000 new Covid cases in 24 hours. That’s the latest nationwide tally for the U.S. And it shows that the number of confirmed new Covid cases is surging. The… Read more

Coronavirus Bankruptcies on The Rise

More than 111 companies have blamed the coronavirus pandemic in bankruptcy filings since early March. The companies with coronavirus bankruptcies range from retailers and restaurants to churches and airlines…. Read more

Unexpected Losers From COVID-19

In a strange twist, Walgreens Boots Alliance (NASDAQ: WBA) has announced a weaker-than-expected quarter – because of COVID-19. Walgreens said its fiscal third-quarter earnings came in at $0.83 per… Read more

Buy the Pandemic Dip

Most market analysts believe the stock markets are going to be range bound for the duration of this coronavirus pandemic. Other analysts disagree. One analyst in particular, who called… Read more

To top